Cannabics Pharmaceuticals, Inc. (CNBX) Safe, Stand
Post# of 38
Posted On: 01/07/2015 5:45:22 PM
Cannabics Pharmaceuticals, Inc. (CNBX) Safe, Standardized Dosage Cannabics SR Capsules An Ideal Product For Burgeoning MMJ Sector
Cannabics Pharmaceuticals, an emerging domestic drug development company with R&D facilities in Israel, which is focused primarily on cannabinoid-based therapies like their flagship product, Cannabics SR, a long-lasting palliative care formulation targeted chiefly at cancer patients, continues expanding its presence in the booming U.S. medical marijuana (MMJ) market. News last month in mid-December that the company has secured engagement in Colorado with Mountain High Products for the manufacturing and distribution of the Cannabics SR extended-release product, comes at an auspicious time, as MMJ retail sales have ballooned to around $300M for the year in Colorado, doing about $32M a month as of late 2014.
Cannabics SR is an ideal product for states like Minnesota and New York, where the recently passed MMJ laws only allow for a 30-day supply of non-smokeable MMJ. Growing receptivity within the medical community and among patients alike has led to unprecedented demand for MMJ to treat a variety of conditions that can be addressed via the increasingly well understood therapeutic properties of cannabinoids. Moreover, many of the conditions for which MMJ is now being prescribed have historically been treated with comparatively more potentially dangerous or habit-forming pharmaceuticals, like opioid derivatives. Consumers are now turning to MMJ for even everyday aches and pains in some cases, seeing MMJ as a relatively benign alternative to the possibly severe and sometimes fatal gastrointestinal bleeding associated with over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs), especially in chronic pain use cases.
Additionally, an oral capsule formulation of cannabinoids, like Cannabics SR, elegantly sidesteps the stigma and potential risks of smoking or vaporizing that many patients dislike, with the added benefit that both elderly and child patients who cannot smoke, are also able to access the therapeutic benefits that such a product has to offer. With the recent landmark FDA approval of a clinical study of cannabidiol (CBD, a non-psychoactive component extracted from cannabis) in childhood epilepsy and a growing number of such studies into the broad-spectrum pain relief, mood elevating and neurological normalizing functions of cannabinoids, the iron is red-hot for a commercial, proprietary formulation that takes advantage of the increasingly promising pharmacokinetics of THC (the psychoactive component of cannabis) and CBD.
Cannabics SR capsules are perfect for patients who are new to MMJ and represent a safe, standardized dosage (10mg of active cannabinoids) that is easy to administer. Unlike most edibles, the amount of THC and the formulation thereof is controlled with Cannabics SR, making the product attractive to new patients, or patients who want to avoid the potentially deleterious psychotropic side effects of a large, unmeasured dosage as is common among edible forms of MMJ.
Comprised of pure, concentrated extracts of carefully selected cannabis strains, Cannabics SR capsules are also completely free of any artificial additives or chemical substances and can easily be double or tripled dosed to achieve therapeutic windows of 8 to 12 (20mg), or 12 to 18 hours (30mg). While it is never recommended for new patients to start a regimen at dosages over 10mg, observational studies have shown a single dose can provide up to 10 to 12 hours of steady-state therapeutic effect on its own, and the rapid onset (20 to 60 minutes) with sustained beneficial effects that is achievable with this formulation, makes the product perfect for once, or twice-daily dosing. It is not unthinkable that such a product could gradually emerge as the standard alternative or companion to common over-the-counter pain medications, as state regulators continue to roll back antiquated restrictions on marijuana.
With nationwide MMJ revenues for 2014 around $2B on only 23 states and DC having created new laws to legalize it, the increasingly inescapable attraction of associated tax revenues for state legislators, like the $7.6M added to Colorado’s state coffers in October 2014, will no doubt continue to put pressure on the remaining states to reform. The future of the market for cannabinoid-based therapy products like Cannabics SR looks solid, but the company isn’t content to rest solely on the laurels of their superb cannabinoid formulation, they are hard at work applying their combined and extensive experience in molecular biology, cancer research and pharmacology to advancing new advanced drugs and therapies, as well as food supplements based on the considerably vast diversity of strains of the cannabis plant.
Learn more about Cannabics Pharmaceuticals by visiting www.cannabics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Cannabics Pharmaceuticals, an emerging domestic drug development company with R&D facilities in Israel, which is focused primarily on cannabinoid-based therapies like their flagship product, Cannabics SR, a long-lasting palliative care formulation targeted chiefly at cancer patients, continues expanding its presence in the booming U.S. medical marijuana (MMJ) market. News last month in mid-December that the company has secured engagement in Colorado with Mountain High Products for the manufacturing and distribution of the Cannabics SR extended-release product, comes at an auspicious time, as MMJ retail sales have ballooned to around $300M for the year in Colorado, doing about $32M a month as of late 2014.
Cannabics SR is an ideal product for states like Minnesota and New York, where the recently passed MMJ laws only allow for a 30-day supply of non-smokeable MMJ. Growing receptivity within the medical community and among patients alike has led to unprecedented demand for MMJ to treat a variety of conditions that can be addressed via the increasingly well understood therapeutic properties of cannabinoids. Moreover, many of the conditions for which MMJ is now being prescribed have historically been treated with comparatively more potentially dangerous or habit-forming pharmaceuticals, like opioid derivatives. Consumers are now turning to MMJ for even everyday aches and pains in some cases, seeing MMJ as a relatively benign alternative to the possibly severe and sometimes fatal gastrointestinal bleeding associated with over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs), especially in chronic pain use cases.
Additionally, an oral capsule formulation of cannabinoids, like Cannabics SR, elegantly sidesteps the stigma and potential risks of smoking or vaporizing that many patients dislike, with the added benefit that both elderly and child patients who cannot smoke, are also able to access the therapeutic benefits that such a product has to offer. With the recent landmark FDA approval of a clinical study of cannabidiol (CBD, a non-psychoactive component extracted from cannabis) in childhood epilepsy and a growing number of such studies into the broad-spectrum pain relief, mood elevating and neurological normalizing functions of cannabinoids, the iron is red-hot for a commercial, proprietary formulation that takes advantage of the increasingly promising pharmacokinetics of THC (the psychoactive component of cannabis) and CBD.
Cannabics SR capsules are perfect for patients who are new to MMJ and represent a safe, standardized dosage (10mg of active cannabinoids) that is easy to administer. Unlike most edibles, the amount of THC and the formulation thereof is controlled with Cannabics SR, making the product attractive to new patients, or patients who want to avoid the potentially deleterious psychotropic side effects of a large, unmeasured dosage as is common among edible forms of MMJ.
Comprised of pure, concentrated extracts of carefully selected cannabis strains, Cannabics SR capsules are also completely free of any artificial additives or chemical substances and can easily be double or tripled dosed to achieve therapeutic windows of 8 to 12 (20mg), or 12 to 18 hours (30mg). While it is never recommended for new patients to start a regimen at dosages over 10mg, observational studies have shown a single dose can provide up to 10 to 12 hours of steady-state therapeutic effect on its own, and the rapid onset (20 to 60 minutes) with sustained beneficial effects that is achievable with this formulation, makes the product perfect for once, or twice-daily dosing. It is not unthinkable that such a product could gradually emerge as the standard alternative or companion to common over-the-counter pain medications, as state regulators continue to roll back antiquated restrictions on marijuana.
With nationwide MMJ revenues for 2014 around $2B on only 23 states and DC having created new laws to legalize it, the increasingly inescapable attraction of associated tax revenues for state legislators, like the $7.6M added to Colorado’s state coffers in October 2014, will no doubt continue to put pressure on the remaining states to reform. The future of the market for cannabinoid-based therapy products like Cannabics SR looks solid, but the company isn’t content to rest solely on the laurels of their superb cannabinoid formulation, they are hard at work applying their combined and extensive experience in molecular biology, cancer research and pharmacology to advancing new advanced drugs and therapies, as well as food supplements based on the considerably vast diversity of strains of the cannabis plant.
Learn more about Cannabics Pharmaceuticals by visiting www.cannabics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)